Catalyst Pharma Partners

Catalyst Pharmaceuticals' stock rose about 5% on Monday after a report that Angelini Pharma is considering a possible takeover. Angelini is reportedly working with advisers, but talks are still at an early stage. The goal of the Italian family-owned company is to expand its global presence. » Más en de.investing.com

Shares of Catalyst Pharmaceuticals climbed to an all-time high of $26.63, rising 25% over the past six months and delivering a year-to-date return of 12.2%. InvestingPro rates the stock as undervalued (P/E 15.65, PEG 0.52) and highlights stronger liquidity versus debt. For Q4 2025 the company reported EPS of $0.68 (expectation $0.31) and revenue of $152.6 million, driven by Firdapse ($97.6M) and Agamree ($35.3M). Oppenheimer reiterated its "Outperform" rating with a $33.00 price target; Catalyst will also present posters on Duchenne research at the MDA conference. » Más en de.investing.com

At the Barclays conference, Catalyst Pharmaceuticals announced 2026 revenue guidance of $615–645 million, driven by Firdapse ($435–450 million) and Agamree ($140–150 million), while Fycompa is expected to decline to $40–45 million due to generics. The company reported 2025 revenue growth of 20%, available cash of over $700 million, and a $200 million share buyback program. Catalyst plans targeted acquisitions or licensing of drugs for rare diseases with peak sales potential of up to $500 million and emphasizes balancing profitability with investments in growth. » Más en de.investing.com

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, exercised and immediately sold 10,983 shares on Nov. 26, 2025, for roughly $256,200, reducing his direct holdings to 3,962 shares. The sale converted vested options into cash and represented about 73% of his prior direct stake. The transaction follows Catalyst's strong Q3 results and raised 2025 revenue guidance, though the sizable insider reduction may warrant investor attention. » Más en finance.yahoo.com

Catalyst Pharmaceuticals reported Q3 2025 EPS of $0.68 (forecast $0.33) and revenue of $148.4M (expectation $136.37M). The company raised its full-year revenue guidance to $565–585M and expects $355–360M for Firdapse and $105–115M for AGAMREE. Total revenue rose 15.3% year over year, liquidity stands at $689.9M with no debt. The stock fell slightly in regular trading but showed a premarket recovery; risks remain from generic competition and ongoing patent disputes. » Más en de.investing.com